New cancer clinical trial: QUILT-3.067: Molecularly Informed Integrated Immunotherapy Combining Innate High-affinity Natural Killer (haNK) Cell Therapy With Adenoviral and Yeast-based Vaccines to Induce T-cell Responses in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy.

Published on: December 29, 2017 at 10:00AM
Condition:   Triple Negative Breast Cancer
Interventions:   Drug: Aldoxorubicin HCl;   Biological: ALT-803;   Biological: ETBX-011;   Biological: ETBX-051;   Biological: ETBX-061;   Biological: GI-4000;   Biological: GI-6207;   Biological: GI-6301;   Biological: haNK for Infusion;   Biological: avelumab;   Biological: bevacizumab;   Drug: Capecitabine;   Drug: Cisplatin;   Drug: Cyclophosphamide;   Drug: Fluorouracil;   Drug: Leucovorin;   Drug: nab-Paclitaxel;   Drug: lovaza;   Procedure: SBRT
Sponsor:   NantKwest, Inc.
Recruiting
http://ift.tt/2Cd5dR9